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Advisory CouncilAexperiencing a conﬂuence of events that pose a signiﬁcant threat to the futurehealth of the nation” (1). Among the converging factors are cutbacks in support for
graduate medical education (GME) and signiﬁcant reductions in funding for medical
research. The scope of the crisis is enormous, and the impacts of inaction are far-reaching
both within our profession as well as for the entire nation.
As we noted in October, the GME crisis alone is threatening “an entire generation of
bright and ambitious physicians who wish to contribute to patient well-being through clinical
care and discovery of new medical knowledge” (1). However, when you couple declining
GME funding with massive cuts in medical research, you have a “perfect storm” that threatens
to undo the extraordinary achievements that we have made over the past 50 years in reducing
death from cardiovascular disease and helping our patients live longer, healthier lives.
The federal government plays an essential role in funding medical research in the United
States, primarily through the National Institutes of Health (NIH), which is made up of
27 institutes and centers, each with a speciﬁc research agenda. Unfortunately, over the last
decade, NIH funding has remained essentially ﬂat. When factoring in the rate of biomedical
inﬂation, the agency has lost approximately $6 billion, or 20%, of its purchasing power since
2003, hindering its ability to fund life-saving research at a sustained pace (2).
According to a recent article in Cardiology Today (3), the likelihood of getting a successful
NIH grant has fallen from 1 in 4 to about 1 in 10 as a result of these cuts. Study investigators
are being forced to reduce staff, extend timeframes, and/or limit studies in order to maintain
their research laboratories. “Newly emerging investigators are particularly vulnerable in this
ﬁscal climate,” the article notes (3).
To make matters worse, the recent sequestration slashed the NIH budget by an additional
$1.5 billion, or a little more than 5%. The Framingham Heart Studydthe longest running
cardiovascular research project in the countrydwas among the victims of the sequestration
cuts, losing $4 million in funding. According to NIH Director Francis Collins, MD, the
agency will try to “prioritize things that seem most promising, most critical to public health,
but there is no question there will be across-the-board damage to virtually everything” (4).
Meanwhile, federal research funding is not the only resource being cut. Industry spending
on research is also waning. For example, biomedical research expenditures by industry have
decreased substantially in the last decade from a compound, inﬂation-adjusted annual
growth rate of 8.1% (1994 to 2003) to 5.8% (2003 to 2007), and this decline is relatively
greater in the domains of cardiovascular research and development (5). In 2010, 13 novel
oncology drugs were approved, but only 3 cardiovascular medications were approved (6).
There is also inadequate research underway in cost-containment strategies, systems of care,
and reductions in healthcare disparities.
Unfortunately, these cuts are coming at a time when we need the funding the most. The
20th century witnessed remarkable advances in the realm of heart disease thanks to the very
research support that is now under ﬁre. However, given a population that is not only growing
but living longer, with a high percentage of risk factors ranging from obesity to hypertension
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1812and high cholesterol, cardiovascular disease is unlikely to lose
its ranking as the number 1 cause of death any time soon. In
fact, according to current projections, there will be a 25%
increase in the prevalence of both heart failure and stroke over
the next 20 years (7).
Without continued, robust investments in research aimed
at improving the entire spectrum of patient care, from
prevention and early detection to diagnosis and treatment,
we cannot hope to meet these challenges head on, and we
stand to lose ground on the hard-fought advances we have
already made to date.
Already there have been exciting advances in regenerative
medicine, personalized medicine, and biomarkersdall of
which hold tremendous promise. For example, cardiac
biomarkers are proving to be important tools when it
comes to better identifying individuals at high risk for
cardiovascular disease, diagnosing disease conditions
promptly and accurately, and effectively treating and
monitoring patients with cardiovascular disease. In addition,
development of novel inhibitors of PCSK9 could change
how we treat patients with lipid disorders.
Also on the drug front, new oral anticoagulants are
already affecting treatment of patients with atrial ﬁbrillation.
Compared with traditional treatment, ongoing research
suggests that these newer drugs can lower bleeding and
stroke risk and that they require less frequent monitoring
and dietary restrictions in some patients.
Beyond drugs, research is also advancing cardiovascular
devices and therapies. Transcatheter aortic valve replacement
is one of the most recent transformational new therapies,
providing options for patients with severe aortic valvular
stenosis who are either high-risk candidates or inoperable
for surgical aortic valve replacement. Percutaneous coronary
intervention (PCI) via radial access versus femoral access is
another growing trend that, thanks to ongoing research,
appears to pose less bleeding risk and shorter recovery times in
patients in whom it is feasible. New data from the American
College of Cardiology’s (ACC’s) CathPCIRegistry show that
the percentage of patients undergoing PCI via a femoral
access site between 2009 and 2011 decreased from 96.5% to
88.8%, whereas the amount of patients undergoing PCI with
radial access increased dramatically from 2.9% to 10.9% (8).
The list goes on and on, which is why the College is
actively engaging in efforts to educate the cardiovascular
community, as well as members of Congress and patients,
about the beneﬁts of cardiovascular research funding and
the need for it to continue.
This past September, the College asked members to stand
with the more than 150 national organizations and institu-
tions participating in the Rally for Medical Research and to
call on our nation’s lawmakers to invest funding for medical
research. In addition, the nearly 400 ACC members whoattended the ACC’s Legislative Conference from September
22 to 24, 2013, in Washington, DC, had an opportunity to
personally meet with lawmakers and their staff to emphasize
the importance of research funding, continued support for
GME, and the need for meaningful payment reforms.
Moving forward, we are asking all members to carry the
message to their lawmakers at both the state and local levels.
We must do a better job of educating our elected and
regulatory ofﬁcials regarding the critical importance of
medical education and research. We must emphasize that
this research has an immeasurable impact on all of our lives
by enhancing public health, lengthening life, reducing the
burden of illness and disability, and most importantly, saving
lives. We also must work together to ﬁnd new, innovative
ways to generate funding, whether through collaborative
public/private initiatives like the Million Hearts campaign or
some other cross-disciplinary alliance not yet imagined.
If we hope to weather this “perfect storm” we must act now
and we must act together, both as a profession and as part of
the broader medical community. Our lawmakers need to hear
from us about the devastating impacts of continued cuts in
research funding, GME support, and other key factors on our
ability to achieve the triple aim of appropriate, high-quality,
cost-effective patient care. The health and well-being of our
entire nation is at stake. Let’s rally!
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